Jury Clears Mead Johnson in First Federal NEC Baby Formula Trial, Inman, et al. v. Mead Johnson & Co. LLC, No. 1:22-cv-03737

If you lost a premature baby to necrotizing enterocolitis after Enfamil or Similac feedings — this verdict doesn’t erase what happened to your family, and it doesn’t decide your case either. A federal jury just cleared Mead Johnson in Inman, et al. v. Mead Johnson & Co. LLC, et al., No. 1:22-cv-03737, the first bellwether trial to reach a verdict in the nationwide NEC baby formula litigation. Here’s what that outcome actually means if you have a claim of your own.

Mead Johnson NEC Bellwether Trial — Key Facts

Category	Details
Verdict Returned	September 1, 2026, after roughly five hours of jury deliberation
Defendant	Mead Johnson & Co. LLC (maker of Enfamil; subsidiary of Reckitt)
Alleged Harm	Wrongful death — plaintiff Alexis Inman alleged Enfamil Premature formula contributed to her premature son Daniel’s fatal necrotizing enterocolitis (NEC) in 2020
Claims Presented	Design defect and failure to warn healthcare providers of NEC risk
Verdict	Full defense verdict — jury rejected both the design defect and failure-to-warn claims; punitive damages phase never reached
Who Is Affected	Families with pending claims in the federal Preterm Infant Nutrition Products Liability MDL, or considering a claim over a premature infant’s NEC diagnosis after cow’s-milk-based formula
Court & Case Number	U.S. District Court for the Northern District of Illinois, No. 1:22-cv-03737; part of MDL No. 3026
Current Stage	Case concluded at the trial court level — first federal bellwether verdict in an MDL covering more than 800 pending complaints against Mead Johnson and Abbott Laboratories
Settlement Status	No settlement — this was a trial verdict, not a settlement, and no money was awarded
Last Updated	September 7, 2026

Who Is Mead Johnson, and Why Was It the First Company to Face a Federal NEC Jury?

Mead Johnson makes Enfamil, including specialty formulas fed to premature infants in neonatal intensive care units, and is now a subsidiary of the British consumer-products company Reckitt. Inman’s case became the test case not because it was chosen at random, but because it survived pretrial motions that knocked out three companion cases against Abbott Laboratories before they ever reached a jury. That made Inman the first real read on how a federal jury would evaluate the core NEC allegations against either manufacturer.

What Did the Jury Decide, and What Did Mead Johnson Argue?

Alexis Inman’s son Daniel was born at roughly 670 grams — just under a pound and a half — and was fed a combination of fortified breast milk, donor milk, and Enfamil Premature before being switched to Enfamil exclusively. He developed NEC and died from NEC-related shock in 2020. Inman argued Mead Johnson’s product was defectively designed and that the company failed to adequately warn her healthcare providers about the NEC risk tied to cow’s-milk-based formula.

Before trial, Mead Johnson tried a different exit: it argued the U.S. Supreme Court’s decision in Monsanto v. Durnell, a case about pesticide-label preemption, should knock out Inman’s claims entirely under federal preemption. U.S. District Judge Rebecca Pallmeyer rejected that argument, ruling the law governing infant formula labeling isn’t the same as the pesticide statute at issue in Monsanto. Mead Johnson also convinced the judge to split the trial in two — the jury would decide liability first, and only reach punitive damages if it found Mead Johnson responsible.

After a two-week trial, the jury took about five hours to reject both claims outright. Liability was rejected. The trial never reached a punitive damages phase, because there was nothing left for punitive damages to attach to.

Losing the preemption argument didn’t cost Mead Johnson this case — the facts in front of the jury did the rest.

Does This Verdict Affect Your Own NEC Claim?

Here’s exactly what a bellwether loss for the plaintiff does and doesn’t mean.

• Anyone with a pending claim in MDL No. 3026 is not automatically affected — bellwether verdicts don’t decide other cases, they only test how juries respond to the evidence
• Families whose case shares Inman’s specific fact pattern — a preemie switched from breast or donor milk to formula shortly before an NEC diagnosis — should expect the defense to lean on this outcome in settlement talks
• People whose case involves Abbott’s Similac products rather than Mead Johnson’s Enfamil line aren’t directly touched by this verdict, since Abbott has had a mixed record of its own
• Anyone still deciding whether to file a claim should know one defense win doesn’t close the door — other juries in this same litigation have returned verdicts in the hundreds of millions against these companies

Where the Rest of the NEC Litigation Stands Right Now

That mixed record is worth walking through, because it explains why one verdict — for either side — doesn’t settle much. In March 2024, an Illinois jury awarded $60 million against Mead Johnson over the death of a premature infant named Chance Dean; an appellate court later overturned that verdict after finding the jury had improperly heard evidence about Mead Johnson’s finances, and the case can now be retried or appealed further. A St. Louis jury cleared Abbott and Mead Johnson in a separate 2024 trial, but the trial judge vacated that defense win and ordered a new trial after finding the defense had repeatedly introduced evidence the court had barred; a Missouri appeals court upheld that retrial order. Mead Johnson won again outright in a June 2026 St. Louis trial.

Abbott’s numbers tell a similar story — see AllAboutLawyer.com’s coverage of Abbott’s own NEC litigation, shareholder claims, and wage disputes for the fuller picture of where that company stands. In July 2024, a St. Louis jury hit Abbott with $495 million — $95 million compensatory and $400 million punitive — over a premature infant left with 75% of her intestines removed after Similac Special Care 24 feedings; a Missouri appellate court upheld that verdict. In April 2026, a Cook County jury awarded $70 million combined to four families in a separate Similac case. Against that backdrop, this Inman defense verdict is Mead Johnson’s cleanest win yet — but it’s one data point in a litigation that has gone hard both directions depending on the facts of the specific baby, the specific product, and the specific jury.

That’s the number that actually matters here: not one verdict, but the spread between them — from a full defense win in Chicago to nearly half a billion dollars against a competitor in St. Louis.

What Should Families With a Pending or Potential NEC Claim Do Right Now?

1. This verdict doesn’t end the MDL. More than 800 complaints remain pending against Mead Johnson and Abbott in the Northern District of Illinois alone, plus parallel state court cases.
2. If you already have a claim filed, ask your attorney directly how the Inman facts compare to yours — the strength of a warning claim often turns on exactly which products a baby was fed and when.
3. Gather your child’s NICU feeding records now if you haven’t already: what was fed, when the formula switch happened, and when NEC symptoms appeared.
4. If you’re still deciding whether to file, know that a single bellwether loss is not a legal deadline — but each state sets its own statute of limitations for wrongful death and product liability claims, so don’t wait indefinitely to consult an attorney.
5. Watch for Mead Johnson’s post-trial motions and any appeal — defense verdicts get challenged too, the same way plaintiff verdicts have been in this litigation.
6. If you’re unsure whether your child’s case fits this litigation at all, a free consultation with a product liability attorney can tell you where you stand.

Mead Johnson NEC Verdict — Frequently Asked Questions, No. 1:22-cv-03737

Is the Mead Johnson NEC lawsuit over now that the jury ruled against Inman?

 No. Inman’s individual case is finished at the trial court level, but it was one bellwether case out of more than 800 pending claims against Mead Johnson and Abbott Laboratories in the same federal MDL, No. 3026, plus separate state court cases.

Do I need to do anything right now because of this verdict?

 Not because of this ruling specifically. If you already have a claim, talk to your attorney about how it may factor into settlement strategy. If you’re considering filing, the verdict doesn’t change your state’s filing deadline.

When will other Mead Johnson or Abbott NEC cases go to trial?

 No confirmed date for the next bellwether trial was available as of this writing. Additional bellwether trials are expected to continue testing claims against both companies.

Can I still file my own NEC lawsuit against Mead Johnson or Abbott after this verdict?

 Yes. A defense verdict in one bellwether case does not bar other families from filing or pursuing their own claims, though it may affect how quickly a company is willing to discuss settlement.

How will I find out about developments in the broader NEC litigation?

 Court filings in MDL No. 3026 are public record in the Northern District of Illinois. Attorneys handling NEC cases also typically notify their own clients directly of major rulings.

What does a “bellwether trial” mean, and why does it matter here?

 A bellwether is a test case selected from a large group of similar lawsuits to see how a jury responds to the shared evidence and arguments. It doesn’t bind other cases, but it shapes how both sides value settlement going forward.

What specific claims did Inman bring against Mead Johnson?

 Inman alleged Mead Johnson’s Enfamil Premature formula was defectively designed and that the company failed to adequately warn her healthcare providers about the NEC risk associated with cow’s-milk-based formula. The jury rejected both claims.

How much money have families won or lost in other NEC baby formula cases?

 Results have varied sharply. A Missouri jury’s $495 million verdict against Abbott was upheld on appeal. A Cook County jury awarded $70 million against Abbott in April 2026. Mead Johnson lost $60 million in March 2024, but that verdict was overturned on appeal, and Mead Johnson won outright in a separate June 2026 trial before this Inman verdict.

Sources Used in This Mead Johnson NEC Article

• Steptoe LLP — “Steptoe Helps Secure Defense Verdict for Mead Johnson in First Bellwether Trial Over Infant Formula and NEC,” Sept. 1, 2026 (official law firm press release, defense counsel): https://www.steptoe.com/en/news-publications/steptoe-helps-secure-defense-verdict-for-mead-johnson-in-first-bellwether-trial-over-infant-formula-and-nec.html
• Levin Papantonio (Levin Law) — “First Federal NEC Baby Formula Bellwether Trial Begins Against Mead Johnson,” Aug. 17, 2026 (official law firm press release, citing Law360): https://levinlaw.com/newsroom/first-federal-nec-baby-formula-bellwether-trial-begins-against-mead-johnson/
• The Associated Press, via NewsTribune.com — “Court upholds $495 million verdict against Abbott,” May 2026: https://www.newstribune.com/news/2026/may/07/court-upholds-495-million-verdict-against-abbott/

Researched and written by Israr Ahmad, legal content researcher and founder of AllAboutLawyer.com. Facts verified against Steptoe’s Sept. 1, 2026 press release and Levin Papantonio’s Aug. 17, 2026 case background on September 7, 2026. Last Updated: September 7, 2026.

This article is for informational purposes only and does not constitute legal advice. Laws vary by state and individual circumstances differ. For advice about your specific situation, consult a qualified attorney.